Bill Taranto

They're continuing to think about strategically how they continue to build out their platforms.

I think that'll, you know, probably occur for most of 26th.

We might see some excess at the end of 26, but certainly in 27, I think some of those will start to move on, which is good.

You know, ultimately, you know, yes, we're a venture capital firm and we're a corporate firm, and we had talked about strategic returns, but ultimately the main mission that drives myself and our staff is we're here to help patients.

We may not ultimately save lives, but we're hoping the assets that we're investing in improves patient outcomes, hopefully saves lives,

reduces costs, creates efficiencies, and provides a better healthcare environment for everyone.

And that's everyone on a global basis.

Everyone has a right and should have access to healthcare.

And that's ultimately what our mission is.

And if we can do that, things like strategic returns and profits for Merck will come.

And that's an old George, George Merck quote, you know, patients come first.

And if we do the right, you know, the right thing by the patient, then everything else follows.

And that's ultimately our mission.

And that's why I've been in this for so long is I feel like I've had some small impact on helping patients.

And, you know, when I retire at some point and look back, you know, A, I want to see obviously the fund continue, but I'll look back at companies we created, the Transcares, the Preventuses of the world, the Lebonzo and say,

You know, I was part of that, and that's helping patients.

And it still exists in the world.

And that gives you a good feeling, right?

It's not really in the end about the money.

It's not really about the street.